Market Cap: $433.25M
PP
Prothena Corporation plc
PRTA
NASDAQUSD
Market Cap: $433.25M
Clinical Milestones Take Center Stage in Prothena’s Feb. 19 Update Dublin-based biotechnology firm Prothena plc is holding a quarterly results release on Feb. 19 that industry watchers expect to use a…
Prothena sets Feb. 19 earnings as a forum for development updates Pipeline progress and program timelines take centre stage Prothena plc is due to report quarterly results on Feb. 19, and the company…
Prothena's Focus on Innovative Therapies in Cardiomyopathy Prothena plc, a biotech company specializing in the discovery and development of novel therapeutics for neurodegenerative diseases and relate…
Innovative Advances in Cardiomyopathy Treatment: Novo Nordisk's Coramitug Trial Insights At the recent American Heart Association's 2025 Scientific Sessions, researchers reveal promising developments…
Prothena's Innovative Positioning in the Biopharmaceutical Landscape Prothena plc, a biotechnology company focused on discovering and developing novel therapies for neurodegenerative diseases, stands…
Prothena plc Advances in Neurodegenerative Disease Treatments Prothena plc is at the forefront of developing innovative therapies for neurodegenerative diseases, a sector that is drawing significant a…
Prothena's Strategic Position in the Biotech Landscape Prothena Corp's recent evaluations by a panel of seven financial analysts reveal a diverse spectrum of opinions regarding the company's strategic…
FDA Mandates Additional MRI Scans for Leqembi Alzheimer’s Treatment The U.S. Food and Drug Administration (FDA) recently announces a new requirement for patients receiving Leqembi (lecanemab) for Alzh…
Prothena's Promising Phase 1 Results in Alzheimer's Treatment Prothena Corporation plc takes a significant stride in the battle against Alzheimer’s disease (AD) with the recent results from its Phase…
Prothena Corp's Upcoming Earnings Report: A Critical Insight into Innovation in Neurodegenerative Therapies Prothena Corp is poised to release its quarterly earnings report on August 4, 2025, marking…
Prothena Advances in AL Amyloidosis Treatment with Phase 3 Trial Results Prothena Corporation plc has recently released pivotal findings from its Phase 3 AFFIRM-AL clinical trial, which investigates t…
Prothena Corporation's Commitment to Addressing Neurodegenerative Diseases Prothena Corporation plc, a late-stage clinical biotechnology firm, is dedicated to advancing treatments for neurodegenerativ…
Prothena's Strategic Vision Amid Leadership Change Prothena Corporation plc, a late-stage clinical biotechnology company dedicated to developing therapeutics for protein dysregulation, faces a pivotal…
Prothena's Strategic Focus Amid Board Changes Prothena Corporation plc, a key player in the biotechnology industry specializing in therapeutics for protein dysregulation, undergoes a significant trans…
Prothena's Commitment to Neurodegenerative Disease Research Prothena Corporation plc stands at the forefront of biotechnology, primarily focused on tackling protein dysregulation linked to neurodegene…
Prothena Corporation Prepares for Q3 Financial Results Amidst Promising Therapeutics Pipeline Prothena Corporation plc, a prominent player in the biotechnology sector, is on the verge of releasing its…